-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ssq98WCVRvkAbMj898ko49REPRmpAXHeWxRAAwo5KV6KXdY++xMoQ9dHSTmKW1LC DZZgfWxJsnw9buk1kmBjrw== 0001144204-11-003744.txt : 20110124 0001144204-11-003744.hdr.sgml : 20110124 20110124172910 ACCESSION NUMBER: 0001144204-11-003744 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 6 FILED AS OF DATE: 20110124 DATE AS OF CHANGE: 20110124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUARK PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000920189 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943192416 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-169584 FILM NUMBER: 11544516 BUSINESS ADDRESS: STREET 1: 6501 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 510-402-4020 MAIL ADDRESS: STREET 1: 6501 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: EXPRESSION SYSTEMS INC DATE OF NAME CHANGE: 20000707 FORMER COMPANY: FORMER CONFORMED NAME: QUARK BIOTECH INC DATE OF NAME CHANGE: 19940314 S-1/A 1 v208841_s1a.htm

As filed with the Securities and Exchange Commission on January 24, 2011

Registration No. 333-169584

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



 

Amendment No. 4
To
Form S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933



 

QUARK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

   
California   2834   94-3192416
(State or other jurisdiction of
incorporation or organization)		   (Primary Standard Industrial
Classification Code Number)		   (I.R.S. Employer
Identification Number)

6501 Dumbarton Circle
Fremont, CA 94555
(510) 402-4020

(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)



 

Daniel Zurr, Ph.D.
Chief Executive Officer
6501 Dumbarton Circle
Fremont, CA 94555
(510) 402-4020

(Name, address, including zip code, and telephone number,
including area code, of agent for service)



 

Copies to:

Robert L. Jones, Esq.
Robert J. Brigham, Esq.
Michael E. Tenta, Esq.
Cooley LLP
3175 Hanover Street
Palo Alto, CA 94304-1130
(650) 843-5000



 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

     
Large accelerated filer o   Accelerated filer o   Non-accelerated filer x   Smaller reporting company o
 

 

 
 



 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 
 

EXPLANATORY NOTE

This Pre-Effective Amendment No. 4 to the Registration Statement on Form S-1 (File No. 333-169584) of Quark Pharmaceuticals, Inc. is being filed solely for the purpose of (a) amending “Part II—Item 16. Exhibits and Financial Statement Schedules” and “Part II—Exhibit Index,” (b) filing herewith Exhibit 10.43, the omitted portions of which have been filed separately with the U.S. Securities and Exchange Commission in connection with the request for confidential treatment of such omitted portions and (c) filing herewith Exhibit 23.3.

 
 

PART II
  
INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the sale of the common stock being registered. All amounts shown are estimates except for the SEC registration fee.

 
  Amount to
be Paid
SEC Registration Fee   $ 1,426  
Blue Sky Qualification Fees And Expenses     *  
Israel Securities Authority fee     *  
Tel Aviv Stock Exchange fee     *  
Printing and Engraving Expenses     *  
Legal Fees and Expenses     *  
Accounting Fees and Expenses     *  
Transfer Agent and Registrar Fees and Expenses     *  
Miscellaneous Expenses     *  
Total     *  

* To be provided by amendment.

Item 14. Indemnification of Directors and Officers.

We are incorporated under the laws of the State of California. Section 317 of the California Corporations Code authorizes a court to award, or a corporation’s Board of Directors to grant, indemnity to directors and officers who are parties or are threatened to be made parties to any proceeding (with certain exceptions) by reason of the fact that the person is or was an agent of the corporation, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with the proceeding if that person acted in good faith and in a manner the person reasonably believed to be in the best interests of the corporation. Section 204 of the California Corporations Code provides that this limitation on liability has no effect on a director’s liability (a) for acts or omissions that involve intentional misconduct or a knowing and culpable violation of law, (b) for acts or omissions that a director believes to be contrary to the best interests of the corporation or its shareholders or that involve the absence of good faith on the part of the director, (c) for any transaction from which a director derived an improper personal benefit, (d) for acts or omissions that show a reckless disregard for the director’s duty to the corporation or its shareholders in circumstances in which the director was aware, or should have been aware, in the ordinary course of performing a director’s duties, of a risk of a serious injury to the corporation or its shareholders, (e) for acts or omissions that constitute an unexcused pattern of inattention that amounts to an abdication of the director’s duty to the corporation or its shareholders, (f) under Section 310 of the law (concerning contracts or transactions between the corporation and a director), or (g) under Section 316 of the law (directors’ liability for improper dividends, loans and guarantees). Section 317 does not extend to acts or omissions of a director in his capacity as an officer. Further, Section 317 has no effect on claims arising under federal or state securities laws and does not affect the availability of injunctions and other equitable remedies available to our shareholders for any violation of a director’s fiduciary duty to us or our shareholders. Although the validity and scope of the legislation underlying Section 317 have not yet been interpreted to any significant extent by the California courts, Section 317 may relieve directors of monetary liability to us for grossly negligent conduct, including conduct in situations involving attempted takeovers of Quark.

In accordance with Section 317, our articles of incorporation eliminate the liability of each of our directors for monetary damages to the fullest extent permissible under California law. Our articles of incorporation further authorize us to provide indemnification to our agents (including our officers and directors), subject to the limitations set forth above. The articles of incorporation and our amended and restated bylaws further provide for indemnification of our officers and directors to the maximum extent

II-1

 
 

permitted by California law, and also permit the indemnification of other corporate agents to the maximum extent permitted by California law at the discretion of our Board of Directors. Additionally, we maintain insurance policies which insure our officers and directors against certain liabilities.

The foregoing summaries are necessarily subject to the complete text of the California Corporations Code, our articles of incorporation, our amended and restated bylaws and the agreements referred to above and are qualified in their entirety by reference thereto.

As permitted by the California Corporations Code, we have entered into indemnity agreements with each of our directors and executive officers, that require us to indemnify such persons against any and all expenses (including attorneys’ fees), witness fees, damages, judgments, fines, settlements and other amounts incurred (including expenses of a derivative action) in connection with any action, suit or proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director, an officer or an employee of Quark or any of its affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder.

At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

We have an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise.

ITEM 15. Recent Sales of Unregistered Securities.

The following list sets forth information regarding all unregistered securities sold by us since our inception through October 31, 2010 and gives effect to a 2.9-for-1 reverse split of our outstanding shares of common stock which became effective June 4, 2007. The shares of preferred stock described below were not recombined under the reverse stock split. However, the conversion ratios of the preferred shares will adjust automatically under provisions contained in our amended and restated articles of incorporation and will give effect to the reverse split upon the conversion of the preferred shares into common shares at the completion of this offering.

(1) We have granted options under our 1994 Stock Option Plan, to purchase 389,644 post-split shares of common stock to our employees, directors, and consultants, having exercise prices ranging from $0.00029 to $1.16 per share. Of these, options to purchase 336,199 shares of common stock have been exercised for aggregate consideration of $162,072.50, at exercise prices ranging from $0.00029 to $1.16 per share.

(2) We have granted options under our 1997 Stock Plan, to purchase 1,237,760 post-split shares of common stock to our employees, directors, and consultants, having exercise prices ranging from $1.16 to $17.40 per share. Of these, options to purchase 47,595 shares of common stock have been exercised for aggregate consideration of $92,300.74, at exercise prices ranging from $1.16 to $17.40 per share.

(3) We have granted options under our 2003 Israeli Stock Plan, to purchase 168,644 post-split shares of common stock to our Israeli employees, directors, and consultants, with an exercise price of $5.80 per share. Of these, options to purchase 1,724 shares of common stock have been exercised for aggregate consideration of $10,000.00.

(4) We have granted options under our 2007 Equity Incentive Plan, to purchase 3,464,961 post-split shares of common stock to our employees and consultants, at exercise prices ranging from $1.10 to $17.40. Of these, options to purchase 57,181 shares of common stock have been exercised for aggregate consideration of $89,586.92, at exercise prices ranging from $1.10 to $7.975 per share.

(5) On January 14, 1994, we issued and sold 1,724,137 post-split shares of our common stock to one of our founders and executive officers for $500.00.

II-2

 
 

(6) On January 14, 1994, we issued and sold 206,896 post-split shares of our common stock to one of our founders and executive officers for $60.00.

(7) On January 14, 1994, we issued and sold 112,068 post-split shares of our common stock to one of our founders and executive officers for $32.50.

(8) On January 14, 1994, we issued and sold 232,758 post-split shares of our common stock to one of our founders and executive officers for $67.50.

(9) On January 14, 1994, we issued and sold 344 post-split shares of our common stock to one of our executive officers for $0.10.

(10) On February 18, 1994, we issued and sold an aggregate of 645,000 shares of our Series A preferred stock (222,409 shares of common stock on an as-converted, post-split basis) to a total of 11 accredited investors for aggregate consideration of $806,250.00.

(11) On March 14, 1994, we issued and sold an aggregate of 543,000 shares of our Series A preferred stock (166,547 shares of common stock on an as-converted, post-split basis) to a total of 14 accredited investors for aggregate consideration of $678,750.00.

(12) On March 31, 1994, we issued and sold an aggregate of 132,000 shares of our Series A preferred stock (45,514 shares of common stock on an as-converted, post-split basis) to a total of 6 accredited investors for aggregate consideration of $165,000.00.

(13) On May 3, 1994, we issued and sold 40,000 shares of our Series A preferred stock (13,793 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $50,000.00.

(14) On June 1, 1995, we issued and sold 4,000,000 shares of our Series B preferred stock (1,379,310 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $5,000,000.00.

(15) On August 30, 1995, we issued and sold an aggregate of 266,824 shares of our Series B preferred stock (75,829 shares of common stock on an as-converted, post-split basis) to a total of 8 accredited investors for aggregate consideration of $333,530.00.

(16) On October 3, 1996, we issued and sold 1,375,000 shares of our Series C preferred stock (474,137 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $5,500,000.00.

(17) On December 31, 1996, we issued and sold an aggregate of 68,692 shares of our Series C preferred stock (23,683 shares of common stock on an as-converted, post-split basis) to a total of 7 accredited investors for aggregate consideration of $274,768.00.

(18) On May 30, 1997, we issued and sold 125,000 shares of our Series C preferred stock (43,103 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $500,000.00.

(19) On August 28, 1997, we issued and sold 5,000,000 shares of our Series D preferred stock (1,724,137 shares of common stock on an as-converted, post-split basis) and issued a warrant to purchase up to 4,125,000 shares of our Series D preferred stock (1,422,413 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $20,000,000.00.

(20) On September 9, 1997, we issued and sold 439,413 shares of our Series D preferred stock (151,521 shares of common stock on an as-converted, post-split basis) and issued a warrant to purchase up to 410,940 shares of our Series D preferred stock (141,703 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $1,757,652.00.

(21) On December 17,1999, we issued and sold 2,034,588 shares of our Series E preferred stock (701,582 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $20,000,000.00.

II-3

 
 

(22) On May 26, 2000, we issued and sold an aggregate of 16,232 shares of our Series E preferred stock (5,594 shares of common stock on an as-converted, post-split basis) to a total of 6 accredited investors for aggregate consideration of $159,569.56.

(23) On March 27, 2001 we issued and sold an aggregate of 458,333 shares of our Series F preferred stock (158,044 shares of common stock on an as-converted, post-split basis) to a total of 2 accredited investors for aggregate consideration of $5,499,996.00.

(24) On April 12, 2001 we issued and sold an aggregate of 335,434 shares of our Series F preferred stock (115,666 shares of common stock on an as-converted, post-split basis) to a total of 2 accredited investors for aggregate consideration of $4,025,208.00.

(25) On June 25, 2001 we issued and sold 250,000 shares of our Series F preferred stock (86,206 shares of common stock on an as-converted, post-split basis) to 1 accredited investor for $3,000,000.00.

(26) On September 30, 2001 we issued and sold an aggregate of 99,997 shares of our Series F preferred stock (34,977 shares of common stock on an as-converted, post-split basis) to a total of 7 accredited investors for aggregate consideration of $1,199,964.00.

(27) On December 27, 2005, we issued and sold an aggregate of 7,342,646 shares of our Series G preferred stock (2,531,945 shares of common stock on an as-converted, post-split basis) and issued warrants to purchase up to 1,468,528 shares of our common stock (506,388 shares of common stock on a post-split basis) to a total of 4 accredited investors for aggregate consideration of $10,499,983.78.

(28) On February 24, 2006, we issued and sold an aggregate of 1,923,086 shares of our Series G preferred stock (663,132 shares of common stock on an as-converted, post-split basis) and issued warrants to purchase up to 384,617 shares of our common stock (132,625 shares of common stock on a post-split basis) to a total of 3 accredited investors for aggregate consideration of $2,750,012.98.

(29) On May 1, 2006, we issued and sold an aggregate of 1,223,779 shares of our Series G preferred stock (421,991 shares of common stock on an as-converted, post-split basis) and issued warrants to purchase up to 244,755 shares of our common stock (84,396 shares of common stock on a post-split basis) to a total of 3 accredited investors for aggregate consideration of $1,750,003.97.

(30) On March 19, 2008, we issued and sold an aggregate of 2,780,000 shares of our Series H preferred stock (2,780,000 shares of common stock on an as-converted, post-split basis) to a total of 3 accredited investors for aggregate consideration of $13,900,000.

(31) On April 7, 2008, we issued and sold an aggregate of 2,620,000 shares of our Series H preferred stock (2,620,000 shares of common stock on an as-converted, post-split basis) to a total of 11 accredited investors for aggregate consideration of $13,100,000.

(32) On May 17, 2010, we issued and sold an aggregate of 2,000,000 shares of our Series H preferred stock (2,000,000 shares of common stock on an as-converted, post-split basis) and issued warrants to purchase up to 300,000 shares of our Series H preferred stock to a total of 9 accredited investors for aggregate consideration of $10,000,000. The warrants issued in this transaction were subsequently exercised on October 18, 2010 for aggregate consideration of $1,500,000.

The offers, sales and issuances of the securities described in Item 15(1) through 15(4) were exempt from registration under the Securities Act under Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of such securities were our employees, directors or consultants and received the securities under our 2007 Equity Incentive Plan, 1997 Stock Plan, 2003 Israeli Stock Option Plan or 1994 Stock Option Plan. Appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions had adequate access, through employment or business relationships, to information about us.

II-4

 
 

The offers, sales, and issuances of the securities described in Items 15(5) through 15(32) were exempt from registration under the Securities Act under Section 4(2) of the Securities Act and Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited or sophisticated person and had adequate access, through employment, business or other relationships, to information about us.

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits.

 
Exhibit
Number		   Description of Document
 3.1*     Amended and Restated Articles of Incorporation of the Registrant, effective March 11, 2008.
 3.2*     Certificate of Amendment of Amended and Restated Articles of Incorporation of the Registrant, effective May 17, 2010.
 3.3*     Amended and Restated Bylaws of the Registrant, as currently in effect.
 4.1      Reference is made to exhibits 3.1 and 3.2.
 4.2*     Specimen Common Stock Certificate.
 4.3*     Fourth Amended and Restated Investor Rights Agreement, dated as of March 19, 2008, by and between the Registrant and the persons and entities named therein.
 4.4*     Form of Series H Preferred Stock Purchase Warrant of Registrant.
 4.5†     Form of Warrant to Purchase Common Stock of Registrant.
 5.1†     Opinion of Cooley LLP.
10.1*#    Form of Indemnitee Agreement between the Registrant and its officers and directors.
10.2*#    Employment Agreement, dated as of January 1, 2008, by and between the Registrant and Daniel Zurr.
10.3      Reserved.
10.4*#    Employment Agreement, dated as of September 14, 1997, by and between QBI Enterprises, Ltd. and Smadar Samira Shakked.
10.5      Reserved.
10.6*#    Employment Agreement, dated as of May 10, 2007, by and between QBI Enterprises, Ltd. and Rami Skaliter.
10.7*#    Employment Agreement, dated as of May 10, 2007, by and between QBI Enterprises, Ltd. and Juliana Friedmann.
10.8*#    Employment Agreement, dated as of March 9, 2003, by and between Registrant and Shai Erlich.
10.9*#    Employment Agreement, dated as of June 28, 2007, by and between QBI Enterprises, Ltd. and Elena Feinstein, M.D., Ph.D.
10.10*#   Employment Agreement, dated as of August 1, 2010, by and between QBI Enterprises, Ltd. and Sagit Reich.
10.11*#    1997 Stock Plan.
10.12*#    1997 Stock Plan for Israeli Employees.
10.13*#    Form of Option Agreement and Form of Option Grant Notice under the 1997 Stock Plan.
10.14*#    Form of Option Agreement and Form of Option Grant Notice under the 1997 Stock Plan for Israeli Employees.
10.15*#    2003 Stock Option Plan for Israeli Employees.
10.16*#    Form of Option Agreement and Form of Option Grant Notice under the 2003 Israeli Stock Option Plan.
10.17*#    2007 Equity Incentive Plan.
10.18*#    Form of Stock Option Agreement and Form of Option Grant Notice under the 2007 Equity Incentive Plan.
10.19*     Lease Agreement, dated September 8, 2006, by and between the Registrant and John Arrillaga, Trustee and Richard T. Peery, Trustee.
10.20*     Lease Contract, dated December 15, 1995, by and between the Registrant and Kiryat Weizmann Science Park Ltd.
10.21*+    Exclusive License Agreement, dated September 3, 1999, by and between the Registrant and The Board of Trustees of The University of Illinois.

II-5

 
 

 
Exhibit
Number		   Description of Document
10.22*+    Collaboration Agreement, dated as of December 6, 2004, by and among the Registrant, QBI Enterprises, Ltd., and Atugen AG (currently Silence Therapeutics).
10.23*+    Option and License Agreement, dated as of April 19, 2005, by and among the Registrant, QBI Enterprises, Ltd., and Atugen AG (currently Silence Therapeutics).
10.24*+    Amendment to Collaboration Agreement, dated as of May 25, 2006, by and among the Registrant, QBI Enterprises, Ltd., and Atugen AG (currently Silence Therapeutics).
10.25*+    Deed of Amendment and Option, dated as of September 25, 2006, by and among the Registrant, Atugen AG, QBI Enterprises, Ltd., and Pfizer Inc.
10.26*+    License Agreement, dated as of September 25, 2006, by and between Registrant and Pfizer Inc.
10.27*+    License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.28*+    License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.29*+    License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.30*+    License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.31*+    First Amendment to the License Agreement between the Board of Trustees of The University of Illinois and the Registrant, dated March 23, 2007.
10.32*+    Amendment Number Two to the License Agreement between the Board of Trustees of The University of Illinois and the Registrant, dated December 22, 2009
10.33*+    Patent License Agreement dated January 29, 2010 with Dharmacon, Inc for the exclusive license of Dharmacon pending patent application covering certain sequences of the p53 gene.
10.34*+    License And Collaboration Agreement between Nitto Denko Corporation and the Registrant, dated June 30, 2010
10.35*+    Option Agreement between Novartis International Pharmaceutical Limited and the Registrant, dated August 17, 2010
10.36†#    2010 Employee Stock Purchase Plan.
10.37*+    Addendum No. 1 to Option and License Agreement, dated as of July 30, 2007, by and between Registrant and Silence Therapeutics AG.
10.38*+    Amendment to License Agreement, dated as of May 19, 2008, by and between Registrant and Pfizer Inc.
10.39*+    Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.40*+    Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.41*+    Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.42*+    Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.43+      Amendment No. 2 to Option and License Agreement, dated as of December 16, 2010, by and between Registrant and Silence Therapeutics AG.
21.1*     List of Subsidiaries of the Registrant.
23.1*     Consent of Independent Registered Public Accounting Firm.
23.2†     Consent of Cooley LLP (included in Exhibit 5.1).
23.3      Consent of Independent Valuation Consultant
24.1*     Power of Attorney (included in signature page).

* Previously filed.
† To be filed by amendment.
# Indicates management contract or compensatory plan.
+ The Company has requested confidential treatment with respect to certain portions of this exhibit, which have been separately filed with the Securities and Exchange Commission.

II-6

 
 

(b) Financial Statement Schedules.

No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the notes thereto.

Item 17. Undertakings.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned Registrant hereby undertakes that:

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-7

 
 

SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on the 24th day of January, 2011.

 
  QUARK PHARMACEUTICALS, INC.
    

By:

/s/ Daniel Zurr, Ph.D.
President and Chief Executive Officer

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

   
Signature   Title   Date
/s/ Daniel Zurr, Ph.D.
Daniel Zurr, Ph.D.		   President, Chief Executive Officer and Director (Principal Executive Officer)   January 24, 2011
/s/ Sagit Reich
Sagit Reich		   Chief Financial Officer
(Principal Financial and Accounting Officer)		   January 24, 2011
*
Philip B. Simon		   Chairman of the Board   January 24, 2011
*
Philip M. Hahn		   Vice-Chairman of the Board   January 24, 2011
*
Yoshitaka Kitao		   Director   January 24, 2011
  
Toshihiro Toyoshima		   Director     
*
Robert Takeuchi		   Director   January 24, 2011
*By: /s/ Daniel Zurr, Ph.D.
Daniel Zurr, Ph.D.
Attorney-in-Fact		       

II-8

 
 

EXHIBIT INDEX

 
Exhibit Number   Description of Document
 3.1*     Amended and Restated Articles of Incorporation of the Registrant, effective March 11, 2008.
 3.2*     Certificate of Amendment of Amended and Restated Articles of Incorporation of the Registrant, effective May 17, 2010.
 3.3*     Amended and Restated Bylaws of the Registrant, as currently in effect.
 4.1      Reference is made to exhibits 3.1 and 3.2.
 4.2*     Specimen Common Stock Certificate.
 4.3*     Fourth Amended and Restated Investor Rights Agreement, dated as of March 19, 2008, by and between the Registrant and the persons and entities named therein.
 4.4*     Form of Series H Preferred Stock Purchase Warrant of Registrant.
 4.5†     Form of Warrant to Purchase Common Stock of Registrant.
 5.1†     Opinion of Cooley LLP.
10.1*#    Form of Indemnitee Agreement between the Registrant and its officers and directors.
10.2*#    Employment Agreement, dated as of January 1, 2008, by and between the Registrant and Daniel Zurr.
10.3      Reserved.
10.4*#    Employment Agreement, dated as of September 14, 1997, by and between QBI Enterprises, Ltd. and Smadar Samira Shakked.
10.5      Reserved
10.6*#    Employment Agreement, dated as of May 10, 2007, by and between QBI Enterprises, Ltd. and Rami Skaliter.
10.7*#    Employment Agreement, dated as of May 10, 2007, by and between QBI Enterprises, Ltd. and Juliana Friedmann.
10.8*#    Employment Agreement, dated as of March 9, 2003, by and between Registrant and Shai Erlich.
10.9*#    Employment Agreement, dated as of June 28, 2007, by and between QBI Enterprises, Ltd. and Elena Feinstein, M.D., Ph.D.
10.10*#   Employment Agreement, dated as of August 1, 2010, by and between QBI Enterprises, Ltd. and Sagit Reich.
10.11*#   1997 Stock Plan.
10.12*#   1997 Stock Option Plan for Israeli Employees.
10.13*#   Form of Option Agreement and Form of Option Grant Notice under the 1997 Stock Plan.
10.14*#   Form of Option Agreement and Form of Option Grant Notice under the 1997 Stock Plan for Israeli Employees.
10.15*#   2003 Stock Plan for Israeli Employees.
10.16*#   Form of Option Agreement and Form of Option Grant Notice under the 2003 Israeli Stock Option Plan.
10.17*#   2007 Equity Incentive Plan.
10.18*#   Form of Stock Option Agreement and Form of Option Grant Notice under the 2007 Equity Incentive Plan.
10.19*    Lease Agreement, dated September 8, 2006, by and between the Registrant and John Arrillaga, Trustee and Richard T. Peery, Trustee.
10.20*    Lease Contract, dated December 15, 1995, by and between the Registrant and Kiryat Weizmann Science Park Ltd.

 
 

 
Exhibit Number   Description of Document
10.21*+     Exclusive License Agreement, dated September 3, 1999, by and between the Registrant and The Board of Trustees of The University of Illinois.
10.22*+     Collaboration Agreement, dated as of December 6, 2004, by and among the Registrant, QBI Enterprises, Ltd., and Atugen AG (currently Silence Therapeutics).
10.23*+     Option and License Agreement, dated as of April 19, 2005, by and among the Registrant, QBI Enterprises, Ltd., and Atugen AG (currently Silence Therapeutics).
10.24*+     Amendment to Collaboration Agreement, dated as of May 25, 2006, by and among the Registrant, QBI Enterprises, Ltd., and Atugen AG (currently Silence Therapeutics).
10.25*+     Deed of Amendment and Option, dated as of September 25, 2006, by and among the Registrant, Atugen AG, QBI Enterprises, Ltd., and Pfizer Inc.
10.26*+     License Agreement, dated as of September 25, 2006, by and between Registrant and Pfizer Inc.
10.27*+     License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.28*+     License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.29*+     License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.30*+     License Agreement, dated as of September 26, 2006, by and between the Registrant and Alnylam Pharmaceuticals, Inc.
10.31*+     First Amendment to the License Agreement between the Board of Trustees of The University of Illinois and the Registrant, dated March 23, 2007.
10.32*+     Amendment Number Two to the License Agreement between the Board of Trustees of The University of Illinois and the Registrant, dated December 22, 2009.
10.33*+     Patent License Agreement dated January 29, 2010 with Dharmacon, Inc. for the exclusive license of Dharmacon pending patent application covering certain sequences of the p53 gene.
10.34*+     License And Collaboration Agreement between Nitto Denko Corporation and the Registrant, dated June 30, 2010
10.35*+     Option Agreement between Novartis International Pharmaceutical Limited and the Registrant, dated August 17, 2010
10.36†#       2010 Employee Stock Purchase Plan.
10.37*+     Addendum No. 1 to Option and License Agreement, dated as of July 30, 2007, by and between Registrant and Silence Therapeutics AG.
10.38*+     Amendment to License Agreement, dated as of May 19, 2008, by and between Registrant and Pfizer Inc.
10.39*+     Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.40*+     Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.41*+     Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.42*+     Amendment No. 1 to License Agreement, dated as of July 30, 2007, by and between Registrant and Alnylam Pharmaceuticals, Inc.
10.43+       Amendment No. 2 to Option and License Agreement, dated as of December 16, 2010, by and between Registrant and Silence Therapeutics AG.
21.1*       List of Subsidiaries of the Registrant.

 
 

 
Exhibit Number   Description of Document
23.1*     Consent of Independent Registered Public Accounting Firm.
23.2†     Consent of Cooley LLP (included in Exhibit 5.1).
23.3      Consent of Independent Valuation Consultant
24.1*     Power of Attorney (included in signature page).

* Previously filed.
† To be filed by amendment.
# Indicates management contract or compensatory plan.
+ The Company has requested confidential treatment with respect to certain portions of this exhibit, which have been separately filed with the Securities and Exchange Commission.

GRAPHIC 2 line.gif GRAPHIC begin 644 line.gif K1TE&.#EA`0`!`(```````/___R'Y!```````+``````!``$```("1`$`.S\_ ` end GRAPHIC 3 spacer.gif GRAPHIC begin 644 spacer.gif K1TE&.#EA`0`!`(```````````"'Y!`$`````+``````!``$```("1`$`.S\_ ` end EX-10.43 4 v208841_ex10-43.htm Unassociated Document
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
 
Exhibit 10.43

Amendment No. 2
To
Option and License Agreement
 
This Amendment (the “Amendment”) to the Option and License Agreement between Silence Therapeutics AG, a company incorporated under the laws of Germany (“Silence”), on the one hand, and Quark Pharmaceuticals, Inc., a California corporation, and QBI Enterprises Ltd., a company incorporated under the laws of the State of Israel (together referred to as “QBI”) (Silence and QBI together being referred to as the “Parties”), is made and entered into as of the 16th day of December, 2010 (the “Amendment Effective Date”).
 
WHEREAS, Silence (formerly known as Atugen AG) and QBI (one entity of which was formerly known as Quark Biotech, Inc.) are parties to an Option and License Agreement dated April 19, 2005, which has been amended by means of Addendum No. 1 dated July 13, 2007 (the “2005 Agreement”); and
 
WHEREAS, by payment made in April 2007, QBI exercised an option under the 2005 Agreement to designate p53 as a QBI Target thereunder; and
 
WHEREAS, QBI entered into an Option Agreement with Novartis International Pharmaceutical Limited dated August 17, 2010 (the “Novartis Agreement”); and
 
WHEREAS, the Parties had different interpretations as to the payments that would be required by QBI to Silence under the 2005 Agreement in respect of funds that QBI has received and may in the future receive pursuant to the Novartis Agreement (inclusive of the License Agreement which is an exhibit thereto); and
 
WHEREAS, the Parties reached written agreement on the payments that QBI will make to Silence in respect of the Novartis Agreement on November 23, 2010 (“Terms of Settlement”), and desire to amend the 2005 Agreement pursuant to the Terms of Settlement and in fulfillment of each Parties obligations thereunder;
 
NOW, THEREFORE, the Parties hereby agree as follows:
 
1.           Definition.  The 2005 Agreement is hereby amended to add a new defined term “p53 Product”, which shall mean any QBI product that inhibits the QBI Target p53 (Official Symbol: TP53 and Name: tumor protein p53 (Li-Fraumerri syndrome) [Homo sapiens], MIM: 191170, GeneID: 7157).
 
2.           Amendment of Section 4.5; Addition of New Section 4.7.
 
(a)           Section 4.5 of the 2005 Agreement is hereby amended to delete the second sentence of such Section and replace it with the following text:
 

 
1.
 
 
“Solely with respect to p53 Products, this share of the Sub-License Revenues shall be [ * ], except as provided in Section 4.7 of this Agreement.  With respect to QBI Products other than p53 Products, this share of the Sub-License Revenues shall depend on the status of the development of the respective QBI Product at the time of the grant of the sub-License as follows:”
 
To be specific, the Parties hereby confirm that Sections 4.5.1 and 4.5.2 of the Agreement shall not apply to p53 Products.
 
(b)           The 2005 Agreement is hereby amended to add a new Section 4.7 which shall read in full as follows:
 
“4.7           Pursuant to Amendment No. 2 to this Agreement, the Parties have agreed that QBI will make the following payments to Silence:
 
(a)           Within [ * ] following the Amendment Effective Date, the sum of $[ * ]; and
 
(b)           Within [ * ] following the occurrence of either of the following events, if such event [ * ], the sum of $[ * ]:
 
(1)           The [ * ]; or
 
(2)           The [ * ].
 
(c)           If neither of the events specified in clause (b) of this Section 4.7 [ * ], then QBI may elect to pay Silence the sum of $[ * ] or [ * ] in any event [ * ] with respect to Sub-License Revenue arising from p53 Products.  If neither of the events specified in clause (b) of this Section 4.7 [ * ], and QBI has not paid Silence the sum of $[ * ] pursuant to clause (c) of this Section 4.7 [ * ], then the first sentence of sentence of Section 4.5 shall be automatically amended as of such date, without any further action of the Parties, to [ * ].  If [ * ] in the sharing ratio of Sub-License Revenues derived from p53 Products occurs, then the $[ * ] payment shall not be due.”
 
3.           Novartis Agreement.  In consideration of the amendment provided for herein, Silence agrees that, with respect to p53 Products, except for the payments provided for in new Section 4.7 of the 2005 Agreement, no payment shall be due from QBI to Silence in respect of the [ * ] payment by Novartis to QBI under the Novartis Agreement.  Silence further agrees that the payments to be made by QBI to Silence pursuant to Section 4.5 of the 2005 Agreement (as amended by this Amendment No. 2) in respect of payments received or to be received by QBI under the Novartis Agreement shall be [ * ] under the 2005 Agreement solely with respect to p53 Products (and in particular, that [ * ] under Section [ * ] of the 2005 Agreement as long as the Novartis Agreement is in effect).  The invoice previously submitted by Silence to QBI for a payment of [ * ] under Section [ * ] of the 2005 Agreement [ * ] is hereby withdrawn.
 
4.           Authorization.  Each Party hereby represents and warrants that the execution and delivery of this Amendment has been duly and validly authorized by all necessary corporate action on the part of such Party, and that this Amendment is a valid and binding agreement of such Party.
 
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
 
2.
 


 
5.           Continuing Force and Effect; General.  The 2005 Agreement, as amended hereby, shall remain in full force and effect.  This Amendment sets forth the entire agreement and understanding between the Parties as to the subject matter hereof and merges all prior discussions and negotiations between them with respect to the subject matter hereof.  Defined terms used but not defined herein shall have the meaning ascribed to them in the 2005 Agreement.
 
6.           Governing Law.  This Amendment shall be construed in accordance with the Laws of Switzerland.
 
IN WITNESS WHEREOF, the Parties have executed this Amendment No. Two as of the Amendment Effective Date by their duty executed representatives, as set forth below.
 
Quark
Quark Pharmaceuticals, Inc. and QBI Enterprises Ltd.
 
By: /s/ D. Zurr            
Daniel Zurr, CEO
 
  
Silence
Silence Therapeutics AG
 
By: /s/  Thomas Christély            
Thomas Christély, CEO
 
 
 
By: /s/  Klaus Giese            
Klaus Giese, CSO
 
 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
 
3.
 

EX-23.3 5 v208841_ex23-3.htm Unassociated Document
Exhibit 23.3
 

 
January 19, 2011
 
Sagit Reich
Chief Financial Officer
Quark Pharmaceuticals, Inc.
6501 Dumbarton Circle
Fremont, CA 94555

 
Subject: WRITTEN CONSENT TO REFERENCE VARIANCE ECONOMIC CONSULTING VALUATION IN S-1 FILING of QUARK
 
PHARMACEUTICALS, INC.
 
We hereby consent to the inclusion in the registration statement on Form S-1 of Quark Pharmaceuticals, Inc. (the "Company") and any amendment thereto (the "Registration Statement") of references to our final reports to the Board of Directors of the Company as of various dates relating to the estimation of the fair value of the common stock of the Company and other equity instruments and to references to our firm's name therein. We also consent to the references to us under the Experts Section in the Registration Statement. However, in giving such consent, we do not admit that we come within the category of person whose consent is required under Section 7 or Section 11 of the Securities Act of 1933, as amended, or the rules and regulations adopted by the Securities and Exchange Commission thereunder, nor do we admit that we are experts with respect to any part of such Registration Statement within the meaning of the term "experts" as used in the Securities Act of 1933, as amended or the rules and regulations of the Securities and Exchange Commission thereunder.
 
Sincerely,
 

 
/s/ VARIANCE ECONOMIC CONSULTING LTD.
 
VARIANCE ECONOMIC CONSULTING
 

 

 

 GRAPHIC 6 logo_variance.jpg GRAPHIC begin 644 logo_variance.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_X0]H17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,3$Z,#$Z M,C0@,34Z,C@Z-#<``````Z`!``,````!``$``*`"``0````!````KZ`#``0` M```!````-0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```XR```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,`"@`P$B``(1`0,1`?_=``0` M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]53'A.F24^7?XP,7ZQ="RF9^%U?/_9^= M8^:S>^*;C^E;2R/HXUK/YAG^"]-=+_B[J??T>OJUO4LS/ORF&O(IRKO5KJLK MA9?33`MM9NQWG\VYA]3'?.OM]5K?4_P"#7`_X MINLNQNHY/0LB6-R@ZZICM"V^K]'ET[3^=96W?_Z#V)(O7S_-]35?/Q?MF';B M^K;C^LTL];'?Z=K)_/IMUV6-1UC?7#K@Z']7GBM[FZS]'3#?SMC MG>K_`%&))>+^KW2.M=9ZWU2@=?ZF_HG2[CCUW,R'"VZP'^:]8>S]#'Z>UOT_ M4K7IC!M:&R3``DF3\RN;Z+7T_P"I?U2QF]1L])S0'Y!`+K+,FX[G5L8W=9=; MO/I,_D5ILKZ\4=.-+^K=+SNGXF0\,KR[F5&MI=_W(%%]MF/_`&V;TE/3I+-Z MU]8.E=!QFY/5+_1K>=K"&N>7.B=L5-=[G+&O_P`8W0JNFUY]5>5DFUCK3BU5 M[K:ZF/=1]IR_=Z6+0]S?8ZZWWI*>AS.I].P75,S>?63K_^+[KF-TW.ZG]IMM;^EQ<1C'LLRYNE'H^K2SW^M_Q5B[ MCJG5<#I&%9G=0M%./7RXZDD_1K8QONLL?^:QJ2FXF7,YOUYIZ8*K^J]+S\'" MN<&-R[&5N8TG_3UT76W4_P!NO>M;K/7ND]&PVYO4<@4T/<&UOVN?N<1N:UOI M!WTFI*=%)ZEUUF/43Z-?M]KKK&*S M]6_KATOZPV9&/CUWXN9BZW8F4ST[`#[?4VM<]NW=[?I)*=U)9O5>O873+J,5 MXLR,W*GT,/';ZESP/IV;9:RNIGY]MSZZUG7_`%TQ\#-HPNL=/S.FNRG"O'N> MQEM+GN.UE;;<*W)_2._C32%D=2^LF)A9]?2Z:[<_J=S=[J MDI__T/1,SKF'@V;,EES!^;9Z;BQW]6QFYJ!_SJZ1/TK/CZ;HU^2UG,:]I98` M]KN6D2/N6'U'ZJT739@N&/9WK,FMW_?JO[/_`&VHY^X/EHI%.VRQEE8LK<'L M<):YNH(\EY#]>L+(^K?UPKZMA@M9E/&=C]AZ["!F4G_CIW/_`/#*[+"SNH=` MM&/FU.^RN/T>PU^G39]#_K:E]?\`I-77OJP[*Q(MOPOUO&DZ=GT=1Z?CY^.9IRJVVL[Z/&_:?Y39VKE.M%W7 M_KST[H@]V%T5HZCGC\TW'VX=3I_.9N]3_B[K%E?XL/K+13T?J&!EOBOIC79M M`G7[.^;+6M^C_-W?^W"W?\7>'D'IF1U_.;&=UZYV6^>U4EN)7_4]/]+5_P`' M:GJ!O9T_K%B?5PLHZGU\5BGISB^E]SB&->[;KZ8.VZSV?HV;'KD?\976+>H? M52TU8&31AFZLC+R6MI#B-Q;Z>*]_VQV__A<>M:O^,#H_6LO(Z/U7I='V\=)O M]:W!+@W>=U;ZWM:[VN_FG5_\'ZGZ.M!^MG3_`*Q?6OZO6U4X+NGLJVW58V0] MCK\A[1_-'8ZRK%J9N?LWV^O?;_W%24]!UUC'_53/:Z+&G`M/N`(,5.(='_26 M5_BTQ<8?4O!>VE@.2VUV20T?I'>I;7NNT_2^P;/=^8I79_7\_P"J]V+^PLIN M=?CNQ2QUF.UF]S#2^W=9DMM]#_K6_P#\^*?U$HZMTSHV+T7J73KL:S%;9^L% M]#Z7!UCK6#]#>^_U/TG^@V?\(DIR_P#&O135T#IK*V-K;7G55U!H`#6^EZUBT=/Z5TRR\8^0W)?D.LH96[:Q[6LJWY`N=[K/=OI8A_73I_U@ZQB] M*ZKA=/L%O2\KU[^DWNJ)LVFMS'_H+;J;6_HWU_SOJ>G=_-)*:_\`C"ZQ;U/Z MH9GH=/R:\/=7^N9+6T-=#V[74XUSOMKVO_X3&H7398:[ZF7!XW`]-=(=J/Y@ MK$^LN%]9?K7T#(QJ\%W3*PT6MHO>QU]]K(:S4ZS=9DLL]#_K6])2O\5]-%?U+P+:Z MVLLN]0VO``O#!'J],!L[2=U8W'_,8M'Z@X_5 M^E]"IZ-U+IUN-;AML(OWTOKLW6.M8QGI7NM]7]+^?5Z7Z/\`GEEMQOK)_P`^ MS]9/V'D?8#C?9?3];%]?AI]7TOM?I?3&W^>^@DI7U)O.?]=/K1GWG?D4V?9: M9_-I99;4*V_N_P!&J>NY?758ZLV-:\L.^O<`2UP&W>S]UVQ[_H;G49_\`RCTTO#+)=[[+*++/T3O>/4^E]/V?0L6U1]8.L93JV4_5 M_,K.YK;GY5E%-;`?IO:YMUUU^UO[E"2GE?J%D]5R>H]?ZKC8]&7E7Y0KN=?> MZES&M+RRNIK<;,]FTL^EZ?T/^#6MUGH7UJZQUWHW4S7A8=72KA8YKM?5NAO4.G]2=OSNFEXJ>'GW>I2ZS] M']-S[&?\9Z7IK8QNN?63-LJ91T%^$QSAZV1G7,8QC9_2;*OLZHRJG)K;CLH%=KW,JY M^KF8[I?4>E%]0;F.RGU9PGUOUEQMVY#-ONV[OL]KV7?I:*Z4J"G2;1TW])7=8E04Z3L?I++A4]S66O^BTVN#CW]K?4W*#:>FV MNH]!IOIO+P+J[MU8VB=?TWOW1L_0MM_EK*J^J%M6(<TU`M>QN53]F_0F/T=_K;KK$*"G4 MJQNEWNQ[*3^E<+B0V1N_2.]3V>URRF? M5G-%-&*Y]+FX;LNQF0=QMO.2R^AM>1/T/Z5ZN5_.^K9CXW_6W'U7?72&-;6` MW$P:!Z3S2X78;WV-R67>G;_--?\`H=U?Z3^:M_1I4%.L,3I#VAP+7,#6G^=) M&U_\T[^M]CB;74M]2Q]?N_T:J9/U>ZO; MZC7VT7.RZNGC*R7`UGU<*[UKG^A6W:YF17_->^OTK/\`@U8JZ'FT=0IRPZIS M&=0R,M[=0?2R*G8[0W3^>KLVO?\`F(4.RFTQO2/0KLR`,4V"0RZ\;QKM^DRZ MRMW]FU';3TJF]E0>UF0?H5&T[CH>*R_W>U857U.O;@.Q;#C.=^R7]-8=KH%C MG/LW_P#$?S?_``B50?5U\N]`7M&#A"24T$&0``````!````!XX M0DE-`_,```````D```````````$`.$))300*```````!```X0DE-)Q`````` M``H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F M9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T````& M```````!.$))30/X``````!P``#_____________________________`^@` M````_____________________________P/H`````/__________________ M__________\#Z`````#_____________________________`^@``#A"24T$ M`````````@`!.$))300"```````$`````#A"24T$,````````@$!.$))300M M```````&``$````".$))300(```````0`````0```D````)``````#A"24T$ M'@``````!``````X0DE-!!H``````TD````&```````````````U````KP`` M``H`50!N`'0`:0!T`&P`90!D`"T`,0````$````````````````````````` M`0``````````````KP```#4``````````````````````0`````````````` M```````````0`````0```````&YU;&P````"````!F)O=6YD'1)D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F M875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP M90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L M;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E M=&QO;F<``````#A"24T$*```````#`````$_\````````#A"24T$%``````` M!`````(X0DE-!`P`````#DX````!````H````#````'@``!:````#C(`&``! M_]C_X``02D9)1@`!`@``2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D M@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P, M$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4 M%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#/_``!$(`#``H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`` M```````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D* M"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R05 M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C M\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`" M`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1B MX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2D MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$# M$0`_`/54QX3IDE/EW^,#%^L70LIF?A=7S_V?G6/FLWOBFX_I6TLCZ.-:S^89 M_@O372_XNZGW]'KZM;U+,S[\IAKR*MCZT=%;UW MH67TTP+;6;L=Y_-N8?4QWSK[?5:WU/\`@UP/^*;K+L;J.3T+(ECYNL_1TPW\[8YWJ_P!1B27B_J]TCK76>M]4 MH'7^IOZ)TNXX]=S,APMNL!_FO6'L_0Q^GM;]/U*UZ8P;6ALDP`))D_,KF^BU M]/\`J7]4L9O4;/2M?6#I70<9N3U2_T:WG:PAKG MESHG;%37>YRQK_\`&-T*KIM>?57E9)M8ZTXM5>ZVNICW4?:EBT/:>F"J_JO2\_!PKG!CWZ22G=26;U7KV%TRZC%>+,C-RI]##QV^I<\#Z=FV6L MKJ9^?;<^NM9U_P!=,?`S:,+K'3\SIKLIPKQ[GL9;2Y[CM96VW"MR?TCOW-B2 MGHTTA9'4OK)B86?7TNFNW/ZGW#Q@"]K./7R+;7U8^/3_*NL387UDHOZF> MD9>/;T_J);ZE6/D;"+6#5S\2_'?=3=Z?Y[-WJI*?_]#T3,ZYAX-FS)9FXL=_5L9N:@?\ZND3]*SX^FZ-?DM9S&O:66`/:[EI$C[EA]1^JM%TV8+ACV M=ZS)K=_WZK^S_P!MJ.?N#Y:*13MLL996+*W!['"6N;J"/)>0_7K"R/JW]<*^ MK88+693QG8_8>NP@9E)_XZ=S_P#PRNRPL[J'0+1CYM3OLKC]'L-?ITV?0_ZV MI?7_`*35U[ZL.RL2+;\+];QG-CW-:"W(K:[^71O]G^EKK1QY.+P(W")#3\GI M.G9]'4>GX^?CF:N=EOGM5);B5_U/3_2U?\`!VIZ@;V=/ZQ8GU<+*.I]?%8I MZT?S1V.LJQ:F;G[-]OK MWV_]Q4E/0==8Q_U4SVNBQIP+3[@"#%3B'1_TEE?XM,7&'U+P7MI8#DMM=DD- M'Z1WJ6U[KM/TOL&SW?F*5V?U_/\`JO=B_L+*;G7X[L4L=9CM9O\MK:\^T.UK*M^0+G>ZSW;Z6(?UTZ?]8.L8O2NJX73[!;TO*]>_I-[JB;-I MK-P/372':C^8*Q/K+A?67ZU]`R,:O!=TRL- M%K:+WL=??:R'-QPVLNIQL?=_A;[/6ML]/]%14K+>H=>R/JH["_8.4W-=BG%# M'/QVLWFLU.LW69++/0_ZUO24K_%?317]2\"VNMK++O4-KP`'.<+;6M-COS_; M^\J5#17_`(WKPP1ZO3`;.TG=6-Q_S&+1^H./U?I?0J>C=2Z=;C6X;;"+]]+Z M[-UCK6,9Z5[K?5_2_GU>E^C_`)Y9;<;ZR?\`/L_63]AY'V`XWV7T_6Q?7X:? M5]+[7Z7TQM_GOH)*5]2;SG_73ZT9]YWY%-GV6F?S:666U"MO[O\`1JGKN7UU M6.K-C6O+#OKW`$M_W+BLSZN]=Z%]9[?K+]7J&YU&?_`,H]-+PR MR7>^RRBRS]$[WCU/I?3]GT+%M4?6#K&4ZME/U?S*SN:VY^59136P'Z;VN;== M=?M;^Y0DIY7ZA9/5G] M#_@UK=9Z%]:NL==Z-U,UX6'5TJX6.:W(LML>USV&]K7_`&.EONIK_FT#(Z!] M8?JU]8LGK7U;H;U#I_4G;\[II>*GAY]WJ4NL_1_3<^QG_&>EZ:V,;KGUDS;* MF4=!?A,MD9US&,8V?TFRG'];(N>YOMJ]E3-Z2G__1]522224PLJKM866- M#V.Y:X2/N*H5])^Q7.LP';:;-;<-^M9)^E94?I4V?^!?\&M))`@6#U"GQ+/^ MJN31]=G?5S&<^NG/MFIS#'ZC:3?>.?V[[1ZS=M=K'JN?JYF.Z7U'I1?4&YCLI]6<)] M;]9<;=N0S;[MN[[/:]EWZ6BNE*@ITFT='+#>U['5M,&SUB6@^&[U-K4C1T<4 MMN+JVT6$;+?5(8Z?H[7;]CMRS;_J]EY>9]KN;CU`VX+CCLES-N&^VXV[]K-U MS_6]*K]'[*J6)4_5[-QLAF0P8]_INZ@&8]DBL,SKFY=;_H/VOKV>C?7M_25W M6)4%.D['Z2RX5/S^<:VXN+3/# M]MCO`PO8=MXJ]:^I][*+-S;G[/IUV>GZMBL]$ MPFNCU*29?Z8V^H[YEC&7VORKZK&;+?5?79=9Z5F]F_\`PB-*;`Q>F;W5-+2]@)>SU7':!XU[ M_:HMIZ-8RQ[7L>RD_I7"XD-D;OTCO4]GMKE?SOJV8^-_UMQ]5WUTAC6U@-Q,&@>D\TN%V&]]CW4'TLBIV.T-T_GJ[ M-KW_`)B%#LIM,;TCT*[,@#%-@D,NO&\:[?I,NLK=_9M1VT]*IO94'M9D'Z%1 MM.XZ'BLO]WM6%5]3KVX#L6PXSG?LE_36':Z!8YS[-_\`Q'\W_P`(E4'U=?+O M0%[1G-<0UQ;>RPXOV2W/LHL:[UL)S?:ST[?^FC04_P#_V3A"24T$(0`````` M50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`G)E M4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE M=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C$M8S`S-B`T-BXR-S8W M,C`L($UO;B!&96(@,3D@,C`P-R`R,CHT,#HP."`@("`@("`@(CX@/')D9CI2 M1$8@>&UL;G,Z&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT7!E+U)E M&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N M8V]M+W!H;W1O&EF+S$N,"\B(&1C.F9O&%P.D-R M96%T;W)4;V]L/2)!9&]B92!0:&]T;W-H;W`@0U,S(%=I;F1O=W,B('AA<#I# M&%P.DUE=&%D M871A1&%T93TB,C`Q,2TP,2TR-%0Q-3HR.#HT-RTP-3HP,"(@>&%P34TZ1&]C M=6UE;G1)1#TB=75I9#HQ1D(W-S@V048X,C=%,#$Q0C=#,4,W1#5&,$0X-S`X M02(@>&%P34TZ26YS=&%N8V5)1#TB=75I9#HR,$(W-S@V048X,C=%,#$Q0C=# M,4,W1#5&,$0X-S`X02(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(@<&AO=&]S M:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(B!P:&]T;W-H;W`Z M2&ES=&]R>3TB(B!T:69F.D]R:65N=&%T:6]N/2(Q(B!T:69F.EA297-O;'5T M:6]N/2(W,C`P,#`O,3`P,#`B('1I9F8Z65)E&EF.E!I>&5L6$1I;65N&EF.E!I>&5L641I M;65N#IX;7!M971A/B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(#P_>'!A M8VME="!E;F0](G0``9&5S8P`````````2D!\@'Z`@," M#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@ M`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`# M[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#04< M!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL& MC`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@? M"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4) M^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY M#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX. M20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y M$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3 M@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L M%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9 MMQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T> M'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@ M\"$<(4@A=2&A(B>K)]PH#2@_*'$HHBC4*08I M."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK M+>$N%BY,+H(NMR[N+R0O6B^1+\< M-]1B)&9T:K1O!'-4=[1\!(!4A+2)%( MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.MT\` M3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755 MPE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R& M7-9=)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=C MZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/ M:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI&>J5[!'MC M>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$ M'82`A..%1X6KA@Z&I+CDTV3MI0@E(J4])5?EAMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>I MJ:H_R#W(O,DZ MR;G*.,JWRS;+MLPUS+7--:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OL MANT1[9SN*.ZT[T#OS/!8\.7Q'EZA8:'B(F*E)66EYB9FJ2EIJ>H MJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$ M`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'1 M0W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3 MX_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH M>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1 M`Q$`/P#?X]^Z]U[W[KW6KS_/^ZB^>W6G7>X_G7\/?FE\ENO,%U]C-M8_MWX_ M;0WW+C-AX[9F.J3C*GL[9]-0J/LMP8Z:K!SZ-)()U&H+I`;W959RJJI+'@!Q M/5))(X8Y)II%2)%)9F(```J22<``9).`.JT_^$^V_OD]_,*[E[3?O'^9;\V: M;,_'VKZM[`VWUCMSLMWVKVEMV7<>7AW7)O9-P8?*QR;;OA\;02XW4"W\7=PQ MTGVHN[2:S">*AJPK@CB.(&?*HR:"M:5&21;#S)MO,1O3M\M5A<`U#@Z34*Q# M(`-15RJJ7(0*7T.QC7>R]I>A!U[W[KW6M=_PH9P'=/3/QZWA\XNG_GG\D_C; MG.M<=U_L?!=+[%W2<=U3VEG]Q[V&+E887'1OFFWQ58?..P9'#,F&_1I]U5@X M#*]^Z]TDMQ[UVCM*3$TNZ-U[?VS)N+(?P?`-F\QCL7)E,HR$#'XO\` MB,X7(9)7L?$%).H<$@@Z`H`!7`^WKQSGI6^]]>Z][]U[KWOW7NO>_=>Z][]U M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__T-_CW[KW7O?NO=)/>VR]L]E;*W3L M+>>)AS.T]\;:S.U=RX>K6T>0P.XL?-CI%J:.H9&L>#_K>_=>Z^9+\< MMS;I_DB?SGSMK?V0K*39W5_:F3Z:W[63LJ?WB^-_9#Z\-OV\WHA:+`9+&;D6 M-BI++P05T^S!+=[J%Y@`?#CR=5#VX`TT_@7&,FI+U[0#[G=[78=RM=ND,JB[ MNP(T$55(E+-)()3)Q-Q+^I4DH@54M@K"9_I_4M535U-!64<\=32U,:S03PL' MCEC<75E8<$$?[;V7]##J1[]U[K5T_F;0#^8Q_-L^$G\LFA4Y;IGX\-)\QOEK M0CR?83R8]!'U[M3)A%A&M\.3'<%G\>\?U"UAX``$``#C_J_;UZM>/5]WR(^8 M7QD^)U'AF[][FV9UK5;C60;0VQ6-7Y;>FZ/L5=YXMJ;"VQ!EMY;H\8@*Z:"@ ME`(TFYX]^Z]T%GQI_F8_!KY@[ORO6WQU^0NU=\]D8&@FR>9ZZJ<1N[9N^L;C MJ.:*&LFJ-I[ZP.U,W&L1D"ZA$0A()N`?==(TZ`*+2F,?LIP_+K=36OGT8KNC MY#]&?'/:L^]>^>W>N^G]K4Z,TV;[`W;B-L4;!576*$Y:>GDR4BNZC3"CMS]+ MBWO9%00#0]:'V=%G[U_F=_`SXS[0ZSWQWG\GNN]CX#NC;F-WUU2M?)E,CN'> M&Q\]C5K\7NO![4VUC,KN^?;4\$MUR`Q_B5;J22K-[WU[JJK^;]\<_P"7U\^] MI_$KY/\`ZV-*>KQ&+P=/7M6K#A:'&)5ME\A,$C&,HZ$'^( M9*MK%B\:B`:F=B"5]7Z=5JA%!KI[O7B?/S_,T]`:#'6ZGA7'^K_-U6QO7^=+ M_+$Z_P`B*+E!_%A@FWAA=L=B[HZWCS!!9<>_9NV-G9?K_[AD4D6R14 MVL#>P-NM=6+;+W[L;LW9."[#V!N[;^\M@[LPT6Z!+9'S$^+^_.S-X=([([TZRWAV=UCLR;? M/8NU]I;JQFX'V'M*CK8<9_%]UUV+`Q>!A>HDL$F:$J%8Z0H!/NO=%9PW\Z'^ M5IN+MNCZ/POS9Z;RO8U3N+^ZM'1465S,FW*K<0:2G;'?Z08L,G6TDGY'^Y8H M3]+,%]^Z]U:'[]U[HCG:_P#,@^%_2VYMT;-WSW;BZG=>Q7`WSMSKK:W8?<6< MV$I4DR;_`,7U+L_>=5LI`I'_`!]>EA\:/G5\1?F1C:_) M_%_Y`=<=R)AR_P#&\;MC,Z-R872IL,UM++18W=N(#/8!IJ`#\6Y'O?7ND[VA M_,'^(?4/95?T[N_N+'97M?#T/\9S76'6>UM_=V;_`-M8A1.6RN[=I]1[2WGF M]FT^I/UY&.%-(%K!@370I`JM:&N7=NUX*F>CFW%A(ZJ MEU?]P7E MK<,R03JSCB*YIC-.-,C-*=6>VN(XEG>%A"QH&H=).GNFJ8*N"* MIII%F@F1)8I%OI>.10Z,+@&S*P(_P/MZ.6.5=4;AEK2H_P!7^H9X=,E2N".M M)W_A6?\`#74O2WSPVABT;Q@?'ON9J=EC.AQD-S]6;CR*H\3R&*89+'NS:KEL M>MM/'LRVF8+>0EL`DKD9&<4XTU$4K_"QX5J`?SY927?+.X^$"[1+XFD,55@H M[M="NH1J3*JUH9(TJ'`T-776%W9F6S7;?QIAI.B.RJJM MB(R.8@VS0K#UYO"<@^**/=>R(X9P@U-<,3I)(+5^(#=W/@1*ENS$A*LV@-GP MR7568QUT,2*,RD@D$$BN"598HIHI0Z,H(8$$,#D,""001D$'@>KENT^R-H]. M=<[[[:WY6IB=G=:[+W-OC=&7>,NN/V]MC%RYG+R756D+&EHB50`ZV4?D#VEZ MZNT\%\LOYIW;N)DH.S?GOW)N3);*6O\\C;9Z*V3G\O1[7PF'D MDF9/X#/DV:,*&/\`Q:TL5''N\DAD(9@`0`,`***`HPH`K0=S<6-68EB2=`4Z M._T/_+XV_P#'[YH?*3^8UW5\D,OV5V)W!C MO=\MDMD[@VKVON[JG.8W*8S+;@3"=YXZ?'9?=&WII<9GJR#:"NR)([?V>2"" M/#3W5!K3'V_/U_EZ^5#1Q(6CT,H4-W5!)(H<`U&DZM)J0PH"M*D,IGO^%27Q M:Z,W+\#MS?*K)]:8*7OSK#=G56"VYV301QP;H_NSN3>%/MK,;;R4_AME,!)! MFA^W(KLI(MI52&M&`S@,&*T)-..!7\OFM5[GWW\A?C-TKF=Z=Y] M@UYS?=^,>KZVPWQ2QWQOQ?>V\^@MH M;URFU:WM+.;)Q,-=N7=W7&/Q=1-DMA1MDJ[&_P`'I<[F)J'[B3UND<1'C/(] MERKIU>A->)/^'A]@QT)2:T^SH"?G/D_A)\;?YBM_\)P,+B>VOY-&R>O^S<9C-X;/R^]^^MBYK;&>B_B.+R&T MLGO#+32;?G@EE\8B*9AQ=0#IY6S:6#UT529BP":FP*BF22`/(BE*4XC(QT@V MFC;;9*MTTY2)5:0A@S,@T.75JLKZ@=:OW*]5;N!ZJ7_EV_`/XU[G_G6?S0/B M;+MG/X[XQ]:;=IZJCZ7PVZ,YCMC;JQD6].MMR8W96]TAE;+[XV5AZVZ^V;L7(IC\GV5L[9F7P%<-M8;#MD,-)@,P5,3,Y]`X`!U;1M#H^D&A!H< M@T\B/3UZ9N8?J;>>W\5X_$1EU(=+KJ!&I6S1A6JFF#0]1/GG_,6[A^,O\@#X MR]P[(W/5P?(/Y`=-?'GJK#;\8!LIB]P;EZP;-[WWS11A4CDS28G:F1>.-F`U MOJ5E(5O=X%5IH@Z,R:A55(5F'F%8A@&(PO:V:=K<#JYN(K6![B=],2TJU"0H M)IJ:G!16K,:*B@LQ502+A_Y7/QFV-\3/@O\`&_K/:5`ARN1ZKVGOOL'<]2M/ M-N+??9F^L/C]T[YW;NC,6BES&WM2M$%%7M`Z];0FWB,9D+=[FI))[G9J=S,<5IQ`QVJJT4$A M_F!=8_'?^5YT-\^OYD?QTZEV_LKY3=K[%Q6TH]W4V(C^UQNX]P9?$[#Q.1V] MAXA!A,'$NX,U_>3)@(LF7F@=BS$E0BC0RR1Q+34Q`_,FF>J7MW'86=W?3!C% M#$\C`4J0BEB!4@5H,5(%?,=%)_D6]\?$WXJ_!'9FY-]9'M&O^0WR*R.Y.\._ M=_0?&_Y)[[R&\MV[FSV6>AB;L3;'3F4PF]8\)C(X85DCKCR[,.&4>U.X0VUO M>3P6DSR6ZF@9E",?6JAF-!H:5Q6@8VB]?<=LL+Z2,JTL2M0@"H(J&TAY` MH848+K8J"`QU`]%YZI[\S6S_`/A0)VC\C.D.D/DOMCX;]X]-9BC[^W74_&GO MG;NW]T[HZ\ZCRF]*O?5/MBJZW3<,NZILCL^,)&M!_&NG<1=HM"&OJ89(GS4<;QIZ*]919!I( M_5[#/,/+5MOEA]&SE5659`,E:J34`:EIK5F6H-!JU4)`Z56]P(Y5:1:KYTP: M>>:']M"?\'5,'R&_EU=O]3PU&>V2*OM/9](\H$>(HYY-V8>@\E1,LM7@81(] M;3*0SRR40D5&?44"ZG$(;WR3O&VT,2M/"H/#BJ@`DZ2>#,7(":@*?$2W1M$R MSFD)U8'H"2:"@%22:G`&2,T&:+/X3?.S(=//1=4]K5-76[#:JAQ^"RU5H678 MO*PFCJ+I'*<$LBG4CZC!(^K5'&)+K.7.>-PV>6WM-PE+6B4C(9!5$52%';I: MJ-2NKQ#H&E=.FCL2VZ2*<9K7_/\`M_P_MZM5^87QWV/\[?AMW-T!65^,J-N] MW];Y7';5&8M<>3<9`6=PMU;QSJ M1GT-1_J/'\^BF1-#E?+K0L_X3T_)GV4S7QJ[*V_7D MN^T^\^O\EETV+D&"I$R,V]OXIMM"P:QS=N2I8FUVL2I:M&!5HQJ(X:AY4S1@ M*:LY)!H*Y"W+UQ?2W&_PWKN$CO7\))!^H(B20X:BZH9'U^!V=BHR"20*-.S) M_P`*$NW=V[JZJ^/G\M[J'(JG=/\`,1[KV[UE.*1E>/#=,;:S^-RG868R9F;_ M`"=`LE`MOTM!%76'`NBZ$W5[_2'46T.@NGNL^D]@T2X[9G5>R=N;%VU1H+"' M%;.Q_P"8K_-5^;^U?YD^[L!5XGXT M[[R6VOC%\.>UMQK0])XS%[3WAO';6Z-YYK8^4OL7LW?&!Q]#C)&?)QR^./., M-)4"WNO=!]\T^_\`INO_`)]7\K;MK9,F%VY\8MC4-1T7MSNN@FQ>W^D]T;CH M,MV)C=S1=?[KI&7#9S;VS MR:>CW1@LC6[G[0Z@QVWZ*DRV$:7+U^)WK'E*N'#B>H#33&+%2`E7=`%%R$9B M7K(+]5&LDP16--3?"NH:06H"2@)U,*-5:BC?"46\PO<;?(B#`>-FH&+%$D1Y M-`4,_BZ%81%`'632R,K@,+8/YB&1QN1BR M$9R&+ZPVO19:@,J7+-BZM1&QN>6'^!*6@J33/1G7R\NJ%?\`A6CO+;6+^)7Q MDVW79BD@S]3\I<1N.@QB5C&O:@V[U[O1:^N%%&"RK"F8`!.DMJ!758A7X8O& M8KK5:`FI(&0,#)'$T'RK7@.B_^U>OLGWUM"49/(;`V9E]F9 M3U M:"I[B%P,Y(&,D#I*_P#"7'LG8.5_EC;>V%1;TP-1O7:7=';=)G]O#*8Y<[C: MC*92//T(DQ[,LI^XPU0)E*QFT8)-K'V]N&I[EO$>LJTJ>WX@*&E!2G$<`P&# M1J]$G*HMDV*R-E;^%9/K:-/U`1&\CLFKQ"6+:2"Q#,A:IC+1E"2J_P`L'L38 M55_PHY_FQ24^[]NS'=6R\E0;:J_XUC4&YJ[;F[>IH]QX[%R*(VRW\!+$D(#H MYMZ>0PU2JG&D"GE7USY^=`3]@.,'$>A9IT77K-&-=97(T@*3V#X*LB$4)ULH M,FIK(O\`A2!N'`8;^4?\D,9DLKBZ+([FK^I\'MZFKJXQ5F7R?^F#9.4EQE!8 M2U+3/%BF)T!K:+6!"^]0A%>(.*Q@BM2>'G4BIX>>3]IZK??4-9W@M6*W1B?0 M5"L0^DZ2%OMK]7=I]:9O+8[;>Y*?-[(Q$FV?[PXS$9 M9X*O(X;=$>$.0A:,.-+%B`!ZG[BW>VE,4A4M0&JL&!#*&!!!(R",<0<,`P(" M6RNX[^UANXE95P]N9S/5SXK$39W+Y'+8O`U=<^$P^)PN.#OD:_P4L<= MPT@^I8H:TIGI9U__T]_CW[KW71`(((!!%B#R"#]01_3WH@$$$5!Z\#3(X]%! M[^^%'2O?S5&3S.%.V]X5#22MO/;24U#E9I3'!"O\40Q/!F$2.+T+,C:3]$2%/#GKDK0'@12NDF@)U4X:J5P"I6"^G\,HS@L!VDC50T`%<@D M```#4`!6E"2>BN=7[:^07P@J8;4A'E("LEKV))&'OT3Q2`P)/:0056II334EC@Z30<07%-1/66`MH0 MF@`SZF@K\J`U`/G@Z?(5_P#=/\MCXX_)'M6/NSO/X%_%/?O:#RXZ2JWCN#=V M\)TPO;OPU!LCXM,X;3\ M-:?"375V5H13O_H=7\)*XD&G[17C]OIG^7SZ07_#:7Q@RF*V[AHKZZ8N)K1E(84H" M25);)7`3@/Q/FOIUXPI@AQ0CS(P<>>:_L'0P=%_%/9?Q9KLODOCS\.?B_P!0 M9;=<*8S<>2ZXW5GMJQY+&TKR5T7\3-%TP)_5,ME`\NB0@EK<&DE[N`6:1+3M M#85M0[:'O+4XUI5:&@X-@GJPBBJBF3)\P1Q]*?X#Z^7#I!=H_`KHWNW>^X.R MNX_Y?WP_[.WSG0JY3=FZL@VY=T972GVIU9G,]-Q-&4!U\A;J"#Z@H-H;N[\$ MF:&LN*:0S?(U!6,"E,T8Y)X``=:>--7:>WYD#[/,_P"`8^?3U1_#CJ_"]-;M M^-V+^#?QCH.B>P;SVVM]9J?/9:@B"F.ADW-GNM-F\ MA5[Z/)J8O_5W!A+"V83G%"K4!]21Q7@*@:OQ:,Z0WX:AJ:@5^T?ZO]5*^?0? MX;^5Y\6L)O/>W9^._EV?$FBWOV5_%5WGD(MRY\RY#^\7E?=+TN+_`-&O\"V] M_'9%%S0L'778G3=5]#=W+M()H"J@=IT-DT'%16E#7@QU#S4C.VC0*I5@3YBH M_P`/^JGSZDX_^5]\3<-E,;FXXQFGTT&I9W"FX"D`C34 M*Q4L-1R`Q520,$J*\!09.\/B+UE\EMU8_>'??PI^+'<^Y\3CAA\=G=][AJMT M9+$8ZG9)AC+Y;IQ@K%\A.5TZU06)^H!:6YN6F:-E*QZ6HVAJDBE"%R1EC4&H MHHX%R%<,:!010FH_$/V$_EY>I],O/07QAV]\89]Q2_'SXA_%WI)-VI2G<:]: M[DS.TFS9Q+%<7'E5Q/3(A98U7Q)W'O?-3/ M6Y3=8W]O7;N[ZS(E3JR.9S.R^L\"^9EG,"/PC2H)..!H,G-0O7GCA!-),GR]/M.?]7YGH=?C[\4MI_$S&U-!\;?A? M\6.G%S*Q466GV#N6;%;@K(5CA!FW9NF'IHY?<`9U5V1VD9@`020/=[BXW)(0 M%MAXWB?A8L"E#FI0D$&@ROS%14#2)"6RW;3SQ0_M%1]AZ#GY)?R_^DOEOF:; M/_(WX'_%GMON\5N*2R6(TER!P.#8*)[T MQHQAA9W%>(95%*'N.DD5'"BGRK0&O5%B)(#,`#\P?\O3QU%_+\^./3G7_975 M?7_P1^+G6VS>V.O]Z;!W]C]I5M6M;V!M3K7CUX@,+,`P/U!`(/Y M^AX^OO3*K@JZ@KZ'/6P2#4&AZJ-_G#_RZHOGU\'NR.G.N,-MV@[?Q&XL9VUT M]5UCG!T@[,P4[15\>1R$:LJP[KVY4U>.=V15'G5BVGD7C8HX<@$`@T(QBF#Z MU_+&/GTQA5_E1?":#X#?!KI3X M^UXQDV^\5C:_=W:]?B6\V/R7:F\:ELGNRHIY)?(X&+DD&.4QLL;)3EK'5?W: M1VD=GO6UO#:6\%I;IIMXD5%%2:*H`45))-``*DDGS/5CWNG3W5 M`/PZ[XWOTC_+TV_\M-][#[%WON[*[,VE@L5N_L'Y%[OW+1=I;W[+[U3KG;:Y M';6XZL.WUWSWQUGO3HGI_<.'Z MIR_9'R)W_NG;>S\]A9]U4NR-M;>V#UYENQMY97WS)ZXWUN;=N8W7-U M[BMQ_$G.=>XV*KV^F.I*?<67VWOZ;L%55F82XIA9U=O0WL?EU[J/US\^.R.Z M-G4VX>LNMMD;>S>V?A7UW\N^P:'?NY,G/C7K^TE['.(ZIV_DL11H*6*GKNJ, MH:['7ND3D_YC/WANG<6 M.['W%COF70[*FQV-C&-P]=@L#5]=2]@*69XYH\JT5E:+]3>%,UX]>Z6]9\I> MQLCN+`[#[5V9@!OSKC^8QUA\=JG*];;\[#VSMBKPF^NG(.U=L[Y^RC_W+YN5 M\+NT464VUE&?#D@DRLJ*5UU[HQWQ7[P[9^2FW\/W53;9V1M?I+=6X.RJ'!X# M)97\MP[(I*W+*D[[0AGR^8VO),]"-+8N-Q'J>36$WBGSZ]T#XK MJGO/^8)W?TOV)N# M&SV[J39DW76/PF/C+2X:G>67CREF]^].O=++-=J;MZY[+S/Q:Z-P=/F:CJOX M]+W_`)7='=_8>Z=P#)XS=^]M[X#8FQ*+` M)-=CKKW16LU_,F[>SG7V\>Z^K^H=A#JCK3XT?$GY49[';UW;F*3>V4VQ\AL5 MO/*;DZ_P(Q.(EV_A<[L;"[8:^0=Y827.J,@@#>,^O7NA6[:^>^]^I\G\M*'/ M;$H-JYOHWJOMKLOJ79N]\/V#0+WO@.M-J;9W')V+L[M/^%1=:[@V-&F9\>8Q M.+,F;PTG#GE@?8^?7ND1\]OD!F]S]8_,/I:'#4^*INJ^KOAMV)3;BILK7+7U MU=W#WCG<7D<2-"1V;`CK>]RP9O,=8Y].NO=2\Y\B.VI,O\AJ+L3^%[NVCL[^ M9/\`%?X]]68/:5?O#J_*[4VWOG,_%^O:?-[CP.6@FWU+AF[+;)'%A%7*LS*X M..(]^Z]TJ\)\V.[*OL_##,=?]OIU[KKJ;YL_('L#&[BW=5],X2IVUA_CK MW1V[-M';S;IDW1@NSNM]W3;;V[T'N#?,VK9B[XSRT%0TBJ$D4QLP1HQ?W[KW M7__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5==2?\`#9'^C'L; M_1U_\U/#^7^K]G7NA9W1_LDOC[=_O+_HM^V_B/ MQU_TSWT_P_\`BW\0V?\`[+-_'/L_]W?=?PO^[?@_:_3^/;7ZFA?A\3%>-/*M M//A6GY5ZWVU/'3G_`&/]GIVR/^RB?WUSO\>_T=_WV_V:;8'\7\G_``)_V:'_ M`$68#_1IY-/I_OU_HM_AW@M^+ZO5J]N>G6NHO5G^RE_Z5-U?Z'OL?[Y_WTWQ M_>'^ZW]]/[E?Z2O-_P`9._@VO_C%G]_M'D_O!_#?]RU[^;]S5[]Z=>ZS?(C_ M`&4W^_77G^F;Q?Z8OX;N3_1I_'_1M_=7_0[U?_`+,!]EY_[L?Z#?[N[P_T2_Q'^$_[ MBO[E?P/^)_PS^$<:;6XT>]"N/MZ]U'S7^R3?WN[L_OM_=/\`B/\`S^XO]X,M_LNG]\_[_\`^_V_ MNQ_%=?\`=KR<:M5O?CU[H6:__9)O])':'\:_NE_>G_3GT%_I:_BG\>_@7^S. M?\8__P!`W\5\7^_*_P!*/B_NSXO'^]?^%Z^='OWEU[I2K_LGO@HOX?\`Z/\` MS_[-UNS^#7^XM_LY?V^[/X]XK\_W_M_$M6GTWU:?5;WKKW5,?2<6U:C;]73] M09#L+$;LI?AO\L:3M;,=8XC?&X^N,[O@X6F7+9[O#;F_LYM;XY[4[+7L?^,/ >A,3MS*YG$'/_`,609(8C]SW;N^=:_P`_\_7NO__9 ` end -----END PRIVACY-ENHANCED MESSAGE-----